Huntsville, ALNCT07783802Now EnrollingIRB Ready

Atherosclerosis Clinical Trial in Huntsville, AL

Access cutting-edge atherosclerosis treatment through this phase 2 clinical trial at a research site in Huntsville. Study-provided care at no cost to qualified participants.

Sponsored by Eli Lilly and Company

Quick Self-Assessment

See if you qualify for this Huntsville location

Preparing your pre-screening questions…

Expert Care in Huntsville

Access atherosclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atherosclerosis treatment provided free

Apply for This Huntsville Location

Check if you qualify for this atherosclerosis clinical trial in Huntsville, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntsville

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntsville site if eligible
  4. 4Begin participation

About This Atherosclerosis Study in Huntsville

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

hsCRP ≥2 mg/L and ≤15 mg/L at screening
At least one of the following chronic conditions:
Established atherosclerotic cardiovascular disease (ASCVD)
Obesity (body mass index (BMI) ≥30 kg/m2)
Type 2 diabetes
Hypertension
Chronic kidney disease Grade 3 or 4

Exclusion Criteria

Acute cardiovascular event within 60 days prior to screening
Acute decompensated heart failure hospitalization within 60 days prior to screening
Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
New York Heart Association Class III or IV heart failure
Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
Type 1 diabetes
Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
Nephrotic syndrome, estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², or history of kidney transplant
Dialysis or acute kidney injury within 60 days prior to screening
Congenital/hereditary kidney disease, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis
Active tuberculosis, untreated latent tuberculosis, or known hepatitis B or hepatitis C infection
Serious, opportunistic, chronic, or recurrent infection requiring treatment within 12 weeks prior to screening
Significant active autoimmune disease
Suspected or confirmed immunocompromised state (e.g., HIV infection)
History of peptic ulcer disease or gastrointestinal ulceration within 12 months prior to screening
History of diverticular disease, gastrointestinal perforation, or major gastrointestinal surgery
Mechanical heart valve prosthesis requiring chronic vitamin K antagonist anticoagulation
Use of colchicine within 14 days prior to screening or anticipated need during the study
Use of immunosuppressive or immunomodulatory agents, including other biologic anti-IL-6 therapies, within specified windows prior to screening
Use of systemic corticosteroids within 14 days prior to screening
Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntsville?

Yes, this clinical trial (NCT07783802) has an active research site in Huntsville, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atherosclerosis Treatment Options in Huntsville, AL

If you're searching for atherosclerosis treatment options in Huntsville, AL, this clinical trial (NCT07783802) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntsville research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced atherosclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Huntsville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntsville, AL